
Opinion|Videos|April 4, 2024
Educating Patients on Adverse Effects Related to Talquetamab in MM
Expert perspectives on educating patients with multiple myeloma on adverse effects related to treatment with talquetamab.
Advertisement
Episodes in this series

Advertisement
Related to this article

Ajai Chari, MD, discussed sequencing CAR T and bispecifics, fixed-duration therapy, emerging targets, and academic partnership in multiple myeloma.

At the 2026 Chemotherapy Foundation Symposium, Ajai Chari, MD, explained how disease pace and BCMA sequencing guide choosing CAR T or bispecifics.

Ralph V. Boccia, MD, FACP, details the home monitoring tools, prophylaxis, and grade-based approach his practice uses to manage CRS.

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.

Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.
Advertisement
Advertisement
Trending on CancerNetwork
1
How Should CAR T and Bispecifics Be Sequenced in Multiple Myeloma?
2
SNO 2026 Shows Lasting Responses, Ongoing Research for Safusidenib
3
Why CAR T May Belong Before Bispecifics in Multiple Myeloma
4
FDA Grants Priority Review to Sonesitatug Vedotin in Pretreated CLDN18.2+ Gastric/GEJ Cancers
5

